Cue Biopharma to Present CUE-401’s TGF-β-Dependent Suppression Data at WIRM March 12
Cue Biopharma showcases in vitro data for CUE-401 at WIRM on March 12, demonstrating TGF-β-dependent suppression of Th1, Th2 and Th17 cytokines in CD4+ memory T cells plus inhibition of plasma cell differentiation and NK cell proliferation. These results underline CUE-401’s dual IL-2/TGF-β mechanism to restore tolerance in autoimmune diseases.
1. Presentation Details
Cue Biopharma will deliver a poster presentation entitled “CUE-401: A Novel Bifunctional TGF-β/IL-2 Fusion Protein for the Treatment of Autoimmune and Inflammatory Diseases” on March 12 from 8:00–11:00 p.m. CET (3:00–6:00 p.m. EDT) at the World Immune Regulation Meeting in Davos.
2. In Vitro Data Highlights
New in vitro results demonstrate that CUE-401 exerts TGF-β-dependent suppression of proinflammatory cytokines (Th1, Th2 and Th17) in CD4+ effector memory T cells. Additional data show CUE-401 preventing activated B cells from differentiating into plasma cells and counteracting IL-2–driven proliferation and cytokine production in natural killer cells.
3. Mechanism of Action
CUE-401 combines an engineered TGF-β moiety with an IL-2 mutein to provide immediate inhibition of diverse inflammatory pathways and expansion or induction of regulatory T cells. This bifunctional approach leverages TGF-β to directly regulate proinflammatory cells while IL-2 expands existing Tregs and promotes FOXP3 expression in conventional CD4+ T cells.
4. Clinical Implications
These findings support CUE-401’s potential to achieve both short-term control of inflammation and long-term immune tolerance in autoimmune conditions. The data may inform dose selection and trial design for upcoming preclinical and clinical studies targeting diseases such as rheumatoid arthritis and lupus.